NCT00740103已完成2 期
Long-term Study of Semapimod (CNI-1493) for Treatment of Moderate to Severe Crohn's Disease With Reference to Study CNI-1493-CD-04, 1 or 3 Days' Treatment vs. Placebo
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 119
- 试验地点
- 26
- 主要终点
- Crohn's disease activity index (CDAI)
研究概览
简要总结
CNI-1493-CD05 is an open-label extension study of CNI-1493-CD04. In the CD05 study, patients are eligible for up to 5 courses of semapimod 60 mg IV x 3 days every 6 - 8 weeks. Primary objective is assessment of the efficacy of cumulative doses of semapimod measured by decrease in Crohn's Disease Activity Index (CDAI).
详细描述
CNI-1493-CD05 is an open-label extension study of CNI-1493-CD04. In the CD05 study, patients are eligible for up to 5 courses of semapimod 60 mg IV x 3 days every 6 - 8 weeks. Primary objective is assessment of the efficacy of cumulative doses of semapimod measured by decrease in Crohn's Disease Activity Index (CDAI). In addition, the safety of repeated courses was measured by recording adverse events over time.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Inclusion Criteria
- •Patients satisfactorily completing study CNI-1493-04 were eligible for participation in this study. Satisfactory completion was defined as follows:
- •The patient met all eligibility criteria for participation in study CNI-1493-04 or was granted an exemption by the medical monitor for factors indicating ineligibility.
- •The patient received at least 2 of the 3 planned doses of study medication.
- •The patient had no adverse event >grade 2 felt to be possibly, probably or definitely related to study medication.
- •The patient underwent all required evaluations, both for safety and efficacy, at baseline and day 29 and, for patients enrolling between days 43 and 57 of study CNI-1493-CD-04, at least one full later evaluation, ie the procedures required at day 43 and/or
- •At baseline for study CNI-1493-CD-05, patients were to meet the same concomitant medication criteria as for study CNI-1493-CD-04:
- •Patients receiving medications for CD were to be on each medication for at least 8 weeks prior to screening and on stable doses of each for at least 2 weeks prior to baseline assessments, with the following exceptions:
- •those on methotrexate were to be on a stable dose for at least 4 weeks and must not be receiving more the 25mg/week
- •those on azathioprine or 6-mercaptopurine on a stable dose for at least 10 weeks
- •those on corticosteroids were to have been on them for at least 2 weeks and on a stable for those 2 weeks. They were not to be receiving more than 20 mg/day prednisone (or equivalent).
- •those on mesalazine were to have been on for at least 6 weeks and on a stable dose for at least 2 weeks
- •those on antibiotics for CD were to have been on for at least 2 weeks and on a stable dose for those 2 weeks
- •Patients who were not using other CD medications were to have stopped any previous use of these agents at least 4 weeks prior to baseline assessment for study CNI-1493-CD-
- •Patients were required to sign informed consent specifically for this study, in addition to the consent for study CNI-1493-CD-
- •Men and women of childbearing potential were to be using a barrier method (diaphragm or condom) of contraception and continue doing so for at least 3 months after last study medication. It was strongly recommended that two forms be used.
- •Patients were to be able to adhere to the study visit schedule and/or protocol requirements.
排除标准
- •Only patients completing CD04 were eligible and must not have met any of the exclusion criteria for that study.
研究组 & 干预措施
1
Experimental
Semapimod 60 mg IV x 3 days q 6 - 8 weeks
干预措施: Semapimod (Drug)
结局指标
主要结局
Crohn's disease activity index (CDAI)
时间窗: Every 6 - 8 weeks
次要结局
- Safety measured by adverse events(Every 6 - 8 weeks)
研究者
研究点 (26)
Loading locations...
相似试验
已完成
2 期
Extension Study of Semapimod 60 mg IV x 3 DaysCrohn's DiseaseNCT00741910Ferring Pharmaceuticals15
已完成
4 期
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster DoseMeningococcal DiseaseNCT01823536Novartis Vaccines465
Enrolling By Invitation
3 期
Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus ErythematosusNCT06475742Viatris Innovation GmbH680
Unknown
不适用
Long-term Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)Crohn's DiseaseNCT02926300Kang Stem Biotech Co., Ltd.24
已完成
3 期
Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese ChildrenAllergic AsthmaNCT01328886Novartis Pharmaceuticals38